Clinical Network Services (UK) Ltd
Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA.
CNS creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.
CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team.
BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time.
With over 15 years’ experience on more than 300 projects, CNS is one of the most experienced providers within the local market and a partner of choice for biotech companies.
CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/ regulatory approach to ensure value is strategically added at every stage of the product development life cycle.
Further information about CNS and its intelligent development services can be found at www.clinical.net.au
Paul CroninDirector, Business Development
Crescendo Biologics Ltd
Crescendo Biologics is focused on the discovery and development of best-in-class Humabody™ VH fragment therapeutics, using its novel transgenic platform. Crescendo is enabling the major VH product formats (multivalent, half-life-extended and topical) for its own pipeline, focused in oncology (immuno-oncology, checkpoint inhibitor and ADC, Humabody Drug Conjugate programmes) and inflammation, and to make it the partner of choice for human VH fragment therapeutics.
Dr Nigel CrockettHead of Business Development
Dr Peter PackCEO
Curileum Discovery Ltd
Curileum Discovery Ltd is an new regenerative medicine company in London focused on identifying the underlying causes of serious gastrointestinal (GI) diseases, and repairing or replacing damaged cells in tissues. Effective tissue regeneration requires activation of endogenous healthy stem cells, rare cells in tissues that are the very source of lifelong tissue renewal.
We are applying three decades of stem cell drug discovery and development experience to unlock a whole new range of therapeutic targets to kill defective stem cells and to activate healthy stem cells to restore health to the intestine.
With access to a large supply of patient tissues and leading clinical collaborators, we can rapidly test hypotheses on defined patient populations to discover and support target development for therapeutics and molecular diagnostics.
We have a proven track record of delivery along with streamlined business, legal, and project management capabilities in our discovery and development partnerships with pharmaceutical companies.
Dr Jeffrey MooreCEO
Custom Pharmaceuticals is a contract development and manufacturing organisation providing formulation development, contract manufacturing and packaging services to an international client base within the pharmaceutical industry for clinical and commercial solid oral dosage products. Areas of specialty are in hormones, controlled substances and extended/modified release based formulations.
Iain McGroartyDirector, Business Development and Project Management
Datatrial is a clinical biometrics and technology organisation specialising in complete study delivery; from our flexible and intuitive platform of technologies to our services and consulting. We offer a full range of services including Data Management, Statistics and Medical Writing.
Our innovative nowEDC™ solution allows you to deliver data capture, verification and validation, query management, data extract, IWRS and real-time reporting in one integrated system.
We are a service-driven company; our goal is to meet timelines, exceed expectations through our proactive approach, and be responsive to and collaborative with our customers. Communication, service and quality are critical to a successful clinical study, while always keeping the patient in mind.
Dr Emma BanksCEO
Miss Amy WrightBuisness Development
Diabetology Limited is an award winning biopharmaceutical company employinga proprietary oral delivery system to administerknown bioactives as well as novel compoundsto transform the treatment outcomes for patients with diabetes.
Our philosophy is to form collaborations & partnerships to further key projects, and to outsource many non-core activities. Thus we are able to keep overheads low, conserving shareholders' resources.
Mr Timothy Broke-SmithChief Operating Officer
Dora Wirth (Languages) Ltd.
exhibiting at booth 55
Established in 1962, Dora Wirth Languages Ltd. (DWL) has over 50 years of excellence in global translation solutions for the life science industry. The DWL approach is built on a solid foundation of experience and in-house medical expertise, using DWL’s well-practised and specially formulated procedures for translation, project management and quality control. DWL's business has grown through a dedication and commitment to quality and service. This is acknowledged by DWL's many long-standing clients and is most clearly demonstrated by their recommendation of DWL to others.
Kim ShoulerBusiness Development Director
Beatriz Puche LopezProject Manager
ERA Consulting UK Ltd
The ERA Consulting Group is one of the longest established and most experienced regulatory affairs and product development consulting groups serving the biopharmaceutical industry.
Our expertise covers quality, nonclinical and clinical aspects, both from the regulatory and development strategy perspective. ERA has the knowledge and experience to assist from conception to registration, and beyond.
ERA has experience with a wide range of products (over 450 products to date), including recombinant DNA and hybridoma technology, synthetic peptides, conventional and advanced vaccines, classical blood products, advanced therapy medicinal products comprising gene therapy, somatic cell therapy and tissue-engineered products. ERA also works with innovative new chemical entities, particularly those indicated for neurological, oncological and immunological diseases.
Our specialised international team of more than 30 full-time professionals includes scientists with a research and development background, those with extensive industry experience and former regulators, offering both breadth and depth of expertise, from which our clients can benefit.
Mr Adam LevyBusiness Development Manager (Europe)
Dr Tim FarriesDirector Regulatory Affairs (Gene and Cell Therapies)
Fahy Gurteen Laboratories
Fahy Gurteen Laboratories (FGL) is a Cambridge-based company specializing on the discovery, development and clinical validation of cancer biomarkers. FGL scientists are working on the development of comprehensive IVD solutions for the stratification of cancer patients on the basis of their cell cycle state. Innovative biomarker profiling is performed using tissue sections and blood samples, employing novel immunohistochemistry and molecular biology approaches. The R&D program at FGL includes the development of primary diagnostic antibodies and automated, high throughput image analysis pipelines to be integrated into diagnostic, prognostic and predictive assays for different tumour types. Moreover, FGL has patented novel assays for biomarker profiling with a high potential for development into products for cancer detection, prognosis and companion diagnostics.
Dr Saroj velamakanniResearch Director
Dr Karsten KoehlerSenior Cell biologist
FranceMed Pharma is a privately owned British company, established since 1981 and is fully integrated. Active in pioneering work in Ethical/OTC R&D, Manufacturing, Distribution, Marketing, Sales and Global out-licensing. Owns a number of worldwide patents & trademarks, protecting all its products which are new-to-the-world, game changing, unique, micro-fine topical sprays that treat high prevalent conditions in Dermatology, Paediatrics, Gynaecology and Emergency Medicine.